pyrrolidine, 2-butyl-1-methyl- | 3447-03-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: pyrrolidine, 2-butyl-1-methyl-
• 英文别名: 1-Methyl-2-butyl-pyrrolidin；2-butyl-1-methyl-pyrrolidine；2-Butyl-1-methyl-pyrrolidin；2-butyl-1-methylpyrrolidine
• CAS: 3447-03-8
• 化学式: C₉H₁₉N
• 分子量: 141.257
• InChiKey: PWVDAYXZBXAOSA-UHFFFAOYSA-N

物化性质

• 沸点：
  40-41 °C(Press: 28 Torr)
• 密度：
  0.829±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N-甲基吡咯烷酮 在 乙醚 、 乙醇 、 镍 作用下， 生成 pyrrolidine, 2-butyl-1-methyl-
  参考文献：
  名称：

  Structure of Monocrotaline. VII.¹ Structure of Retronecine and Related Bases

  摘要：

  DOI：

  10.1021/ja01263a020

文献信息

• Benzene, Pyridine, and Pyridazine Derivatives
  申请人：Huang He Kenneth

  公开号：US20080076813A1

  公开（公告）日：2008-03-27

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein A, Q 1 , Q 2 , Q 3 , R 3 , and R 4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明涉及公式I的化合物和药用可接受的盐，其中A、Q1、Q2、Q3、R3和R4如本文所定义。公式I的化合物在治疗与细胞增殖相关的疾病和/或病况方面具有用途，如癌症、炎症、关节炎、血管生成等。还公开了包括本发明化合物的药物组合物以及使用这些化合物治疗上述病况的方法。
• SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS
  申请人：Bignan Gilles

  公开号：US20110294780A1

  公开（公告）日：2011-12-01

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及式(I)的化合物，制备这些化合物的方法，组合物，中间体及其衍生物，并用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿关节炎，感染性关节炎，儿童关节炎，银屑病性关节炎，反应性关节炎），与骨相关的疾病（包括与骨形成有关的疾病），乳腺癌（包括对抗雌激素治疗无效的癌症），心血管疾病，软骨相关疾病（如软骨损伤/丧失，软骨退化以及与软骨形成有关的疾病），软骨发育不良，软骨肉瘤，慢性腰部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺疾病，糖尿病，能量稳态紊乱，痛风，假性痛风，脂质紊乱，代谢综合征，多发性骨髓瘤，肥胖，骨关节炎，遗传性骨发育不全，骨溶解性骨转移，软骨软化症，骨质疏松症，帕金森病，牙周病，多肌痛风，Reiter综合征，重复性应激损伤，高血糖，血糖水平升高和胰岛素抵抗等病症的方法。
• Novel high affinity thiophene-based and furan-based kinase ligands
  申请人：Deng Yongqi

  公开号：US20070043045A1

  公开（公告）日：2007-02-22

  Inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

  描述了抑制细胞周期依赖性激酶2（CDK-2）的抑制剂、包括这些抑制剂的组合物，以及使用这些抑制剂和抑制剂组合物的方法。这些抑制剂和包括它们的组合物对于治疗疾病或疾病症状是有用的。该发明还提供了制备CDK-2抑制剂化合物的方法、抑制CDK-2的方法，以及治疗疾病或疾病症状的方法。
• Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
  申请人：Unoki Gen

  公开号：US20070072898A1

  公开（公告）日：2007-03-29

  A pyrazolo[1,5-a]pyridine derivative represented by formula (I) and salt thereof exhibit excellent MAPKAP-K2 inhibitory activity. Accordingly, medicines comprising this compound as an active ingredient are expected to be valuable for treating or preventing diseases mediated by MAPKAP-K2 such as inflammatory injury, autoimmune diseases, asteropathia destruens, cancer and/or growth of tumor.

  由式(I)表示的吡唑并[1,5-a]吡啶衍生物及其盐表现出优异的MAPKAP-K2抑制活性。因此，包含该化合物作为活性成分的药物预计对治疗或预防由MAPKAP-K2介导的疾病，如炎症损伤、自身免疫疾病、asteropathia destruens、癌症和/或肿瘤生长具有重要价值。
• NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
  申请人：ROTH Gerald Juergen

  公开号：US20120157425A1

  公开（公告）日：2012-06-21

  The invention relates to new piperidine derivatives of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  该发明涉及新的哌啶衍生物，其化学式I，用作药物，用于治疗的方法以及含有它们的药物组合物。